Source comparison
BPC-157 Studied Golfer's Elbow: Research vs Clinical Reality Comparison
Dosage 10–20 mcg/kg body weight (rat studies) 200–500 mcg daily (human equivalent calculation) No pharmacokinetic data in humans. Dosing is extrapolated Dosing remains speculative without human trials Administration Route Subcutaneous or intramuscular injectio
This comparison does not assign a generated winner or score.
- Dosage
- 10–20 mcg/kg body weight (rat studies)
- 200–500 mcg daily (human equivalent calculation)
- No pharmacokinetic data in humans. Dosing is extrapolated
- Dosing remains speculative without human trials
- Administration Route
- Subcutaneous or intramuscular injection near injury site
- Subcutaneous injection (systemic or local)
- Unknown whether local vs systemic produces different outcomes
- Local injection theoretically superior but unproven
- Treatment Duration
- 14–28 days in controlled studies
- 14–30 days in typical protocols
- Optimal duration unknown. Animal timelines may not translate
- Four-week ceiling appears consistent across contexts
- Evidence Quality
- Peer-reviewed animal studies with controls
- Case reports and anecdotal accounts only
- Zero randomised controlled trials in humans
- Gap between mechanism data and clinical validation is substantial
- Safety Profile
- No adverse events in animal models at therapeutic doses
- Minimal reported side effects in off-label use
- No long-term human safety data. Unknown carcinogenic or systemic risks
- Absence of evidence is not evidence of safety
- Regulatory Status
- Investigational compound. Not approved for any indication
- Off-label use under informed consent frameworks
- FDA has issued warning letters to suppliers marketing BPC-157 as supplement
- Legal status ambiguous. Peptide exists in regulatory grey zone